We call ourselves the College of Psychiatric and Neurologic Pharmacists, but how many of us have the training or clinical experience to say we are truly experts in neurology? I definitely treat patients with neurologic issues, but my primary area of expertise is in treating psychiatric illnesses. I think this may be true for many of our members, which is why this issue of the MHC focuses on neurologic disease states. In order to increase our knowledge of Parkinson's disease (PD), multiple sclerosis (MS), and restless leg syndrome (RLS), I reached out to experts within CPNP, in addition to non-members, to educate us on those various disease states.

When treating Parkinson's disease (PD), I immediately think of drug-induced Parkinsonism for which I would use various anticholinergic medications. PD, which affects about 500,000 Americans, can result in a much more complicated treatment scenario however. Did you know that the most recent guidelines include clozapine as a treatment for dyskinesia? Read the review on the treatment of Parkinson's disease in this issue to find out more.

Also included in this issue is a comprehensive review of the pathophysiology and treatment of RLS as well as a look at the new and upcoming treatments for MS. In addition to the neurology topics, there is a toolbox discussing the use of medications to treat primary insomnia and an interesting case report of secondary delusional parasitosis treated with high-dose quetiapine.

My goal with this issue is to educate you, the readership, on these neurologic disease states and hopefully increase your knowledge base in the area of neurology.